- Home
- NUVL vs WEX Comparison
NUVL vs WEX Comparison
Compare NUVL & WEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- WEX
- Stock Information
- Founded
- NUVL 2017
- WEX 1983
- Country
- NUVL United States
- WEX United States
- Employees
- NUVL N/A
- WEX N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- WEX Business Services
- Sector
- NUVL Health Care
- WEX Consumer Discretionary
- Exchange
- NUVL Nasdaq
- WEX Nasdaq
- Market Cap
- NUVL 5.6B
- WEX 4.8B
- IPO Year
- NUVL 2021
- WEX 2005
- Fundamental
- Price
- NUVL $75.00
- WEX $140.74
- Analyst Decision
- NUVL Strong Buy
- WEX Buy
- Analyst Count
- NUVL 8
- WEX 12
- Target Price
- NUVL $115.50
- WEX $181.30
- AVG Volume (30 Days)
- NUVL 452.9K
- WEX 497.8K
- Earning Date
- NUVL 08-07-2025
- WEX 07-24-2025
- Dividend Yield
- NUVL N/A
- WEX N/A
- EPS Growth
- NUVL N/A
- WEX 26.46
- EPS
- NUVL N/A
- WEX 7.78
- Revenue
- NUVL N/A
- WEX $2,612,100,000.00
- Revenue This Year
- NUVL N/A
- WEX N/A
- Revenue Next Year
- NUVL N/A
- WEX $5.19
- P/E Ratio
- NUVL N/A
- WEX $17.90
- Revenue Growth
- NUVL N/A
- WEX 0.90
- 52 Week Low
- NUVL $55.54
- WEX $110.45
- 52 Week High
- NUVL $113.51
- WEX $217.47
- Technical
- Relative Strength Index (RSI)
- NUVL 48.73
- WEX 54.97
- Support Level
- NUVL $76.42
- WEX $138.08
- Resistance Level
- NUVL $78.94
- WEX $145.64
- Average True Range (ATR)
- NUVL 2.71
- WEX 3.82
- MACD
- NUVL -0.34
- WEX 0.19
- Stochastic Oscillator
- NUVL 31.73
- WEX 70.68
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About WEX WEX Inc. common stock
WEX Inc is a provider of corporate payment solutions. The company operates three business segments: Mobility, Benefits, and Corporate Payments. Mobility segment, the top segment by revenue, provides fleet vehicle payment solutions, transaction processing, and information management services for commercial and government fleets. The Corporate Payments segment offers business-to-business payment processing and transaction monitoring services. The Benefits segment generates revenue from healthcare payment products and its consumer-directed software platform. Wex's largest end market is the United States of America.